Exton, Pennsylvania, Jan. 10, 2024 (GLOBE NEWSWIRE) -- In late October 2023, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as the ...

NICE has recommended broadening NHS use of Novartis' IL-17 inhibitor Cosentyx to include children aged six to 17 with severe plaque psoriasis. The cost-effectiveness agency says in draft guidance that ...

Cost regulators for the NHS in England and Wales are backing UCB's Cimzia and Novartis' Cosentyx as treatment options for adults with active psoriatic arthritis. Cost regulators for the NHS in England ...

(RTTNews) - Novartis (NVS) said Friday that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA has adopted a positive opinion for Cosentyx (secukinumab) ...

China Health Authority NMPA approved Cosentyx ® (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Cosentyx is the first ...

Approvals based on data from the JUNIPERA trial, showing that Cosentyx ® (secukinumab) reduced the risk of flare and disease activity compared to placebo over 2 years in pediatric patients 1 with ...

(MENAFN- GlobeNewsWire - Nasdaq) Despite the expanded armamentarium, Cosentyx has not impacted dermatologists' perceived unmet need for new HS treatment options, according to Spherix Global Insights.

The European Commission has approved Cosentyx for the treatment of various childhood arthritic conditions. Novartis announced on June 27, 2022 that the European Commission (EC) has approved Cozentyc ...